BCI
TVTX icon

Brinker Capital Investments’s Travere Therapeutics TVTX Stock Holding History

Brinker Capital Investments’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.01M Sell
17,720
-130
-0.7% -$5.76K 0.01% 1159
2026
Q1 		$530K Sell
17,850
-744
-4% -$22.2K ﹤0.01% 1423
2025
Q4 		$710K Buy
+18,594
New +$605K 0.01% 1427

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Brinker Capital Investments's TVTX Position: Q2 2026 in Review

Brinker Capital Investments reduced its Travere Therapeutics (TVTX) stake by 0.73% in Q2 2026, selling an estimated $5.76K and leaving 17,720 shares worth $1.01M. The position accounts for 0.01% of the portfolio, ranked #1159.

Brinker Capital Investments first reported a position in TVTX in Q4 2025 and has held it in 3 quarters since. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Brinker Capital Investments held 17,720 shares of Travere Therapeutics worth $1.01M as of Q2 2026.
  • Brinker Capital Investments sold 130 Travere Therapeutics shares in Q2 2026, an estimated $5.76K.
  • Travere Therapeutics made up 0.01% of Brinker Capital Investments's portfolio in Q2 2026, its #1159 holding.
  • Brinker Capital Investments first reported a position in Travere Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Brinker Capital Investments's 13F filing for Q2 2026, filed 14 Aug 2026.